ACRO Applauds Passage of 21st Century Cures Act

WASHINGTON--(BUSINESS WIRE)-- Doug Peddicord, PhD, Executive Director of the Association of Clinical Research Organizations, released the following statement on passage of the 21st Century Cures Act by the House and Senate.

“The Association of Clinical Research Organizations commends the House and Senate for passing the 21st Century Cures Act and sending it to President Obama for his signature into law. ACRO is especially pleased with provisions regarding the use of real –world evidence, innovative clinical trial designs, enhancements to clinicaltrials.gov, patient-focused drug development, and funding that supports the FDA, the Cancer Moonshot and Precision Medicine Initiative. Our members are actively engaged with research sponsors, clinical investigators, regulators and, importantly, patients to ensure the full vision of Cures is realized in short order. We especially want to thank Chairman Upton and Representative DeGette for their tireless work on this landmark legislation.”

About ACRO

The Association of Clinical Research Organizations (ACRO) represents companies that provide a variety of specialized services that support the development of new pharmaceuticals, biologics, and medical devices. The Association provides an active voice for the CRO industry globally. Through its member companies, ACRO helps improve the quality, efficiency and safety of biomedical research. ACRO member companies employ more than 130,000 professionals worldwide and conduct research in more than 100 countries. For more information, please visit www.acrohealth.org. Twitter @acrohealth. YouTube @ACROHealthChannel. Facebook. LinkedIn.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161207006215/en/

Association of Clinical Research Organizations
John Lewis, 202-464-9340
[email protected]

Source: Association of Clinical Research Organizations (ACRO)

You May Also Be Interested In

• Merck's tulisokibart meets goals in skin disease Phase 2b trial
• European Medicines Agency Validates Biosplice’s Application for Lorecivivint (LOR) in Knee Osteoarthritis and Begins Review
• The Ensign Group Adds New Operations in Colorado